Dr. Puzanov is an Associate Professor of Medicine in the Division of Hematology-Oncology at Vanderbilt University Medical Center, Nashville, Tennessee.
Dr. Puzanov joined the faculty in July of 2005 after completing a three-year fellowship in Hematology-Oncology at same center.
He completed his residency in Internal Medicine at University of Texas Southwestern Medical Center at Dallas and was board certified in 2001.
Prior to that, he received his M.D. degree from Charles University in Prague.
Dr. Puzanov is an Associate Director of the Phase I Program, Director of Melanoma Clinical Research and Clinical Director of Renal Cell Carcinoma.
In these roles, he is responsible for the development of new innovative therapies for patients with melanoma and RCC as well as co-leadership of a Phase I Program with emphasis on the genomic data integration and immunotherapy concepts.
He leads collaborations with the cardiology department to study cardiotoxicity of anti-VEGF therapies for cancer and with Radiation Oncology department on the synergistic effects between radiation and immunotherapies.
For information please contact email@example.com